Bluebird Stock Analysis

BLUE
 Stock
  

USD 6.33  0.63  11.05%   

The latest price surge of Bluebird Bio could raise concerns from shareholders as the firm is trading at a share price of 6.33 on 8,806,356 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.03. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Bluebird Bio partners.
Continue to Trending Equities.
  
The Bluebird Bio stock analysis report makes it easy to digest most publicly released information about Bluebird Bio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bluebird Stock analysis module also helps to analyze the Bluebird Bio price relationship with some important fundamental indicators such as market cap and management efficiency.

Bluebird Stock Analysis Notes

About 73.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bluebird Bio has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 9.95. The firm had not issued any dividends in recent years. Bluebird Bio had a split on the 5th of November 2021. bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Bluebird Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 518 people. For more info on Bluebird Bio please contact Nick Leschly at 339 499 9300 or go to https://www.bluebirdbio.com.

Bluebird Bio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bluebird Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bluebird Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bluebird Bio is way too risky over 90 days horizon
Bluebird Bio appears to be risky and price may revert if volatility continues
Bluebird Bio has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 4.71 M. Net Loss for the year was (563.29 M) with loss before overhead, payroll, taxes, and interest of (351.14 M).
Bluebird Bio currently holds about 211.59 M in cash with (557.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.96.
Roughly 73.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.benzinga.com: US Stock Futures Mixed After Recording Losses Last Week Fed Speakers In Focus - bluebird bio NASDAQBLU - Benzinga

Bluebird Bio Upcoming and Recent Events

Earnings reports are used by Bluebird Bio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bluebird Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Bluebird Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bluebird Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bluebird Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bluebird Bio specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
9th of September 2022
Unclassified Corporate Event
View
17th of August 2022
Financial Statements and Exhibits. Other Events
View
4th of August 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
1st of August 2022
Unclassified Corporate Event
View
11th of July 2022
Unclassified Corporate Event
View
23rd of June 2022
Submission of Matters to a Vote of Security Holders
View
22nd of June 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View

Bluebird Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Bluebird Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bluebird Bio backward and forwards among themselves. Bluebird Bio's institutional investor refers to the entity that pools money to purchase Bluebird Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon Shares6.1 M25.4 M
Tang Capital Management LlcCommon Shares5.9 M24.5 M
Blackrock IncCommon Shares5.8 M24.1 M
Vanguard Group IncCommon Shares3.5 M14.5 M
Renaissance Technologies LlcCommon Shares2.8 M11.6 M
Baker Bros Advisors LpCommon Shares2.5 M10.3 M
Millennium Management LlcCommon Shares2.5 M10.3 M
Note, although Bluebird Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bluebird Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 394 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bluebird Bio's market, we take the total number of its shares issued and multiply it by Bluebird Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (31.44) % which means that it has lost $31.44 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (76.97) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio management efficiency ratios could be used to measure how well bluebird bio manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 30th of September, Bluebird Bio shows the Downside Deviation of 6.72, risk adjusted performance of 0.1281, and Mean Deviation of 5.79. Bluebird Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Bluebird Bio, which can be compared to its rivals. Please confirm Bluebird Bio variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Bluebird Bio is priced correctly, providing market reflects its regular price of 6.33 per share. Given that Bluebird Bio has jensen alpha of 0.9292, we suggest you to validate Bluebird Bio's prevailing market performance to make sure the company can sustain itself at a future point.

Bluebird Bio Price Movement Analysis

The output start index for this execution was sixty with a total number of output elements of one. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Bluebird Bio changes than the simple moving average.
.

Bluebird Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluebird Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluebird Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bluebird Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bluebird Bio Predictive Daily Indicators

Bluebird Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bluebird Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bluebird Bio Forecast Models

Bluebird Bio time-series forecasting models is one of many Bluebird Bio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bluebird Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Bluebird Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bluebird Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bluebird shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Bluebird Bio. By using and applying Bluebird Stock analysis, traders can create a robust methodology for identifying Bluebird entry and exit points for their positions.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Bluebird Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 518 people.

Current Bluebird Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bluebird analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bluebird analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
19.9Hold10Odds
Bluebird Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bluebird analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bluebird stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bluebird Bio, talking to its executives and customers, or listening to Bluebird conference calls.
Bluebird Analyst Advice Details

Bluebird Stock Analysis Indicators

Bluebird Bio stock analysis indicators help investors evaluate how Bluebird Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bluebird Bio shares will generate the highest return on investment. By understating and applying Bluebird Bio stock analysis, traders can identify Bluebird Bio position entry and exit signals to maximize returns.
Quick Ratio1.55
Fifty Two Week Low2.87
Revenue Growth117.60%
Shares Short Prior Month17.51M
Average Daily Volume Last 10 Day12.66M
Average Daily Volume In Three Month8.34M
Shares Percent Shares Out18.76%
Short Percent Of Float26.50%
Forward Price Earnings-2.32
Float Shares67.04M
Fifty Two Week High17.85
Enterprise Value To Ebitda-0.35
Fifty Day Average5.78
Two Hundred Day Average5.78
Enterprise Value To Revenue39.92
Continue to Trending Equities. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for analysis

When running Bluebird Bio price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Bluebird Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bluebird Bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Bluebird Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.